The Efficacy and Safety of Adding Chlorpromazine to Atazanavir/Ritonavir Regimen in the Treatment of Moderate COVID-19 Patients, a Randomized Double-blind Clinical Trial.

Kame/aninejad, Sima; Namvar, Hamid Reza; Sohrabi, Masoumeh; Darvishnia, David; Ahangar, Nematollah; A]ikhani, Ahmad; Abbaspour, Hamideh; Valadan, Reza; Akbari, Zahra; Akbari, Jafar; Ghasemian, Roya; Salehifar, Ebrahim

Background: According to COVID-19 mutation and no defined treatment, it is necessary to find effective treatment. Cltlorpromazine, a phenothiazine antipsychotic drug, has been shown in animal šfudies to have antiviral effects by inhibiting clathrin-mediated endocytosis. The aim of litis flndy was to evaluate the effectiveness of adding cltlorpromazine to lite atazanavir/ ritonavir regimen in the treatment of moderate COVID-19 patients. Methods: In this randomized double-blind clinical trial, sixty hospitalized patients «iill moderate COVID-19 confinned by CT findings or polymerase chain reaction (PCR) were enrolled. All patients received atazanavir/ritonavir 300mg/100mg once daily. In two parallel groups, chlorpromazine 25 rng three times a day or a placebo was administered for up to 14 days. Complete blood count with differential, C-reactive protein (CRP), liver enzymes, and erythrocyte sedimentation rate was measured on days 1, 3, 5, 7, and 10. The primary outcome was Ute improvement of oxygen saturation and the secondary outcome was Ute duration of hospitalization and conversion of PCR teit results. Results: Oxygen saturation during lite hospitalization was not different among lite two groups. The mean duration of hospitalization in the cltlorpromazine group was 7.4±2.7 days and in the placebo was 8.2±3 days (P=0.2). Compared to baseline, both groups showed an increase in white blood cell count (P=0.04) and polymorphonuclear cells (P=0.04) but lymphocyte count decreased. At the end of the šļudy, the PCR tešt was negative in 100% of patients in lite cltlorpromazine gro up and 95% of patients in the placebo group. Conclusior In adult hospitalized patients with moderate symptomatic COVID-19, adding cltlorpromazine to the atazanavir/ritonavir regimen did not improve outcomes.

C-reactive protein; LIVER function tests; ATAZANAVIR; COVID-19; COMBINATION drug therapy; CHLORPROMAZINE; OXYGEN saturation; TREATMENT effectiveness; RANDOMIZED controlled trials; COMPARATIVE studies; RITONAVIR; BLIND experiment; BLOOD sedimentation; HOSPITAL care; DESCRIPTIVE statistics; RESEARCH funding; STATISTICAL sampling; POLYMERASE chain reaction; BLOOD cell count; EVALUATION

Pharmaceutical & Biomedical Research, 2023, Vol 9, Issue 3, p211

2423-4486

Academic Journal

10.32598/PBR.9.3.1084.1